Himadri Speciality Chemical Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Himadri Speciality Chemical Ltd trades at ₹781, in a confirmed uptrend and 16 weeks into that stage. That is +33.5% against its own 200-day average. It sits at 98% of a 52-week range of ₹438 to ₹790. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 7 straight weeks.

Today the stock is in a confirmed uptrend — week 16 of stage 2, confirmed. At ₹781 it trades +33.5% versus its 200-day average and sits at 98% of its 52-week range (₹438–₹790).

Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +5,142% while the NIFTY 500 moved +284% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 7 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Himadri Speciality Chemical Ltd's story is not scored yet against the markers our research file set on 19 July 2026. Where it sits in its own cycle: Not stated in the research file. Our fortnightly research layers last read it on 19 July 2026.

Our read, 19 July 2026. Himadri has delivered a material operating-profit step-up and is extending its carbon platform into battery materials, but funding quality and conversion of the new projects matter more than the headline earnings trajectory because working capital has absorbed cash and normalized earnings do not make the shares look inexpensive.

What is proven. Himadri has delivered a material operating-profit step-up and is extending its carbon platform into battery materials, but funding quality and conversion of the new projects matter more than the headline earnings trajectory because working capital has absorbed cash and normalized earnings do not make the shares look inexpensive.

What is not proven yet. The case improves if operating margin holds while revenue grows, operating cash conversion recovers without a further extension of the cash cycle, and phased battery-material milestones convert into customer-qualified production. It breaks if investment requires incremental leverage, the cash cycle keeps lengthening, the margin contracts further, or project timing slips again without a clear commercial bridge.

🚨 What would change our mind. The case improves if operating margin holds while revenue grows, operating cash conversion recovers without a further extension of the cash cycle, and phased battery-material milestones convert into customer-qualified production. It breaks if investment requires incremental leverage, the cash cycle keeps lengthening, the margin contracts further, or project timing slips again without a clear commercial bridge.

🚨 Layer 1 read, 19 July 2026 — DROP. Real quality earnings step-up, but already re-rated, extended, and richly priced with soft cash conversion. Himadri's engine is genuine — EPS 2.29 to 4.55 over 12 quarters, PAT +36% in FY26 with OPM near 20% — and battery-material optionality is real. But the stock has run 9.12x off its trough to a peak (78th-percentile PE, normalized-PE +71% above its own median, MoS -51.9%) — this is mid/late-cycle, not a fresh trough. Cash is the counterweight: FY26 OCF/PAT was only 0.51x and the cash-conversion cycle lengthened 90 to 103 days.

What would change Layer 1’s mind. Per the timeline's own kill-switch: it breaks if the FY28-FY31 investment needs incremental LEVERAGE (contradicting the FCF-funded commitment), the cash cycle keeps lengthening, operating margin contracts further, or battery-material milestones slip again without a commercial bridge. Conversely, OCF/PAT recovering toward 0.8x while margin holds and cathode qualifies would re-rate it upward.

The test written in advance. Cash-conversion and working-capital strain — Cash-conversion and working-capital strain Operating cash weakens again while inventory or receivable days rise and project spending accelerates. by the next result.

The test written in advance. Margin normalization — Margin normalization Operating margin falls while revenue growth and cash conversion fail to compensate. by the next result.

What the company does. The core business is generating higher operating profit on only modest annual revenue growth, which supports the mix-improvement case. The latest quarter sustained year-on-year profit growth but did not re-establish the earlier operating-margin high. Management has an ambitious, funded project agenda, yet customer approvals, phased commissioning, cash conversion and valuation are the gates to a better risk-reward view.

🚨 What the surface reading misses. The surface reading is: The annual result shows a substantial earnings step-up. The research reads it further: Operating profit and PAT both advanced ahead of revenue, so the improvement is not merely a sales-growth result.

🚨 What the surface reading misses. The surface reading is: Low annual revenue growth could imply a low-growth earnings profile. The research reads it further: Operating profit and PAT grew substantially faster than revenue, which is consistent with mix, efficiency or utilization improvement rather than simple volume growth.

Lever 2 · Value-added mix — BUILDING. Operating profit has advanced faster than revenue, leaving product mix and utilization as the critical proof points. What proves it keeps working: Mix-led operating improvement. It stops working if Revenue grows while operating margin declines further, or the company cannot explain the margin bridge through product mix, utilization and costs.

Lever 1 · Operating leverage — BUILDING. The carbon platform can create operating leverage if utilization and forward integration convert into reported sales and margin. What proves it keeps working: Carbon platform expansion. It stops working if Utilization does not rise, new products do not generate reported contribution, or margin falls despite the expanded platform.

Sources: our stock research file (19 July 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Himadri Speciality Chemical Ltd reported ₹1,432 Cr of revenue in the Jun 26 quarter, +28.1% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 14.7% a year. The last full year, FY26, came in at ₹4,661 Cr. The last four reported quarters add to ₹4,975 Cr.

Why this happened. The annual and quarterly records show higher operating profit alongside revenue growth. Management attributes the strategic direction to higher-value products and energy materials, but the absence of a blended forward margin guide means the result must be followed through reported margins rather than accepted as a permanent reset.

FY26 revenue came in at ₹4,661 Cr (+1.0% on the year), capping 10 years at 14.7% compound. The latest quarter (Jun 26) printed ₹1,432 Cr, +28.1% year on year — the 3rd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +9.9% growth against the decade's 14.7% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +9.8% over the last 4 quarters against +5.9%/yr over the last 8 — accelerating; TTM profit +31.6% vs +34.0%/yr — stabilising.

FY26-Q4. revenue ₹1,288 Cr and profit ₹208 Cr as reported.

FY27-Q1. revenue ₹1,432 Cr and profit ₹228 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Himadri Speciality Chemical Ltd's operating margin is 20.0% in the Jun 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0% to 23.0%. The current quarter sits inside that band.

Why this happened. Management describes additional utilization, forward integration and new specialty products as routes to improve the established platform. This driver is monitored through reported utilization, revenue and margin rather than management ambition.

The latest quarter's operating margin is 20.0%, −2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0%–23.0%.

🚨 Why the margin moved: operating margin went −1.8 pp year on year while gross margin went −0.3 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY26-Q4. revenue ₹1,288 Cr and profit ₹208 Cr as reported.

FY27-Q1. revenue ₹1,432 Cr and profit ₹228 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Himadri Speciality Chemical Ltd earned ₹228 Cr of net profit in the Jun 26 quarter, +27.4% year on year. It is the 12th consecutive quarter of growth. Full-year FY26 profit was ₹755 Cr. That is 15.9% of the quarter's revenue. The same quarter a year earlier earned ₹179 Cr.

Jun 26 profit was ₹228 Cr, +27.4% year on year — the 12th consecutive quarter of growth. On the full year, FY26 printed ₹755 Cr (+36.0%).

Why profit moved: revenue contributed +28.1% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +31.8% vs revenue +9.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

FY26-Q4. revenue ₹1,288 Cr and profit ₹208 Cr as reported.

FY27-Q1. revenue ₹1,432 Cr and profit ₹228 Cr as reported.

Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 72% of Himadri Speciality Chemical Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹382 Cr of operating cash against ₹755 Cr of profit. After ₹592 Cr of capital spending, ₹−210 Cr was left as free cash.

FY26: operating cash of ₹382 Cr against reported profit of ₹755 Cr, leaving free cash of ₹−210 Cr after ₹592 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 72% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 72%: the cash cycle tightened 52 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 5.1× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Himadri Speciality Chemical Ltd's cash conversion cycle runs 103 days in FY26, down from 155 days in FY21. Capital spending ran ₹878 Cr over the last 3 years. At FY26 sales of ₹4,661 Cr each day of that cycle holds about ₹12.8 Cr, so roughly ₹1,315 Cr sits inside the business at any moment.

FY26: debtors at 55 days, inventory at 96 days — roughly 3.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 103 days, tighter than FY21's 155.

The full loop: cash goes out to suppliers and production on day 0; stock waits 96 days to sell; customers pay about 55 days after that; and suppliers themselves are paid at 47 days — netting out to the 103-day cycle.

In money terms: at FY26 sales of ₹4,661 Cr, each day of the cycle holds about ₹12.8 Cr — so the 103-day loop keeps roughly ₹1,315 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹878 Cr over the last 3 fiscal years against ₹173 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹372 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Himadri Speciality Chemical Ltd earns a ROCE of 22% in FY26. That is up from a trough of 2% in FY14. Return on invested capital clears the cost of that capital by +2.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 16.2% net margin on 0.74× asset turns.

FY26 ROCE is 22%, recovered from a FY14 trough of 2% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 16.2% net margin × 0.74× asset turns × 1.34× balance-sheet leverage ≈ 16.1% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 14.8% − 12.0% = a +2.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Himadri Speciality Chemical Ltd carries total debt of ₹770 Cr against shareholder equity of ₹4,762 Cr as of Jun 26, a debt-to-equity of 0.16 — effectively unlevered. On the annual view that ratio went from 0.31 in FY22 to 0.16 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Jun 26: total debt of ₹770 Cr against shareholder equity of ₹4,762 Cr — a debt-to-equity of 0.16. On the annual view, debt-to-equity went from 0.31 (FY22) to 0.16 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters added 2.3 points of Himadri Speciality Chemical Ltd over 8 quarters, the biggest move on the register. That takes promoters to 52.5% of the company. Foreign institutions moved +1.6 points over the same window, to 6.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +2.3 points over 8 quarters to 52.5%; Foreign institutions: +1.6 points over 8 quarters to 6.8%; Domestic institutions: +1.1 points over 8 quarters to 3.3%.

Why the register moved: promoters drove it (+2.3 points), alongside foreign institutions (+1.6 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Himadri Speciality Chemical Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Himadri Speciality Chemical Ltd trades at 49.3× P/E, at the pricey end of its own range (81st percentile). Its long-run median P/E is 34.1×, measured across 9.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 49.3× is at the pricey end of its own range (81st percentile), against a long-run median of 34.1× measured over 9.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved +32.4% against a +67.4% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +73.3%/yr price move, ~+55.0%/yr came from earnings growth and ~+18.3 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

At its price on 20 July 2026, Himadri Speciality Chemical Ltd was priced for profit growth of about 24.6% a year. The market pays that at 49.3× P/E, the 81st percentile of its own 9-year range.

What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is the whole of what a buyer is backing. Both readings sit on the same earnings, so they are one reading rather than two.

How to hold this number: it is a reading of one day's price, taken on 20 July 2026, not a running figure. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements. Every other number on this page is read off the live quote.

Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Himadri Speciality Chemical Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 24.8% and holding. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.

4-Factor Sector Score

64.3/100 — rank 1 of 2 in Carbon Black · 97% evidence confidence

Himadri Speciality Chemical Ltd scores 64.3 out of 100 against the 2 companies it is compared with in Carbon Black, ranking 1. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 18.6 + 19.6 + 9.7 + 16.4 = 64.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Himadri Speciality Chemical Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Birla Tyres Revenue Target Timeline Extended · 16 July 2026. In the Apr 2026 call, management stated they expected to reach INR 3,000 crores of top line from Birla Tyres in the next 4 years, using the word "expect." In the Jul 2026 call, this was revised to a "target" of 3,000 crores in the next 4 to 5 years, representing both a timeline extension and a subtle reduction in confidence language without explicit explanation for the change.

Anode Material Facility Location Discrepancy · 16 July 2026. In the Apr 2026 call, management stated the anode material facility was commissioned at Mahistikry, West Bengal. In the Jul 2026 call, the same facility commissioned in April 2026 was described as being located at Budge Budge. These are distinct locations in West Bengal, and no explanation was provided for the discrepancy.

Birla Tyres Operating Entity Name Change · 16 July 2026. In the Jan 2026 call, management identified their Birla Tyres operating partner as Dalmia Refractory Bharat Limited, describing a buy-sell arrangement through that entity. In the Jul 2026 call, the entity was referred to as Gallon Refractory, with no explanation for the name change or whether the underlying business arrangement had been restructured.

LFP Commercial Ramp-Up Delay · 21 January 2026. Management previously guided for full-scale operations of the LFP cathode plant to commence in FY28. However, in the latest call, this timeline has shifted, with management now stating that 'big utilization' will only come in FY29 and utilization in FY28 will not be significant. Earlier call (Jul 2025): “The project is progressing as scheduled and is expected to be operational by Q3 FY ‘27, with full-scale operations commencing in FY ‘28.” Later call (Jan 2026): “There won”.

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions